These 2020 ESMO Clinical Practice Guidelines synthesize evidence-based recommendations for managing bone health across the cancer spectrum. They cover diagnosis and imaging of bone metastases, indications for bone-targeted agents, surgical decision-making for pathologic fractures, radionuclide therapy, adjuvant bisphosphonate use in early breast cancer, and prevention of cancer treatment-induced bone loss.
Two denosumab rules every orthopedic trainee must know: first, denosumab must stay on a strict every-4-weeks schedule because it does not accumulate in bone — any gap in dosing risks rebound osteolysis. Second, when denosumab is stopped after more than 6 months, bridging with a single dose of zoledronate 4–5 mg is required to prevent rebound vertebral fractures. Neither rule applies to bisphosphonates.
When evaluating a long bone lesion in a cancer patient, apply the prophylactic fixation thresholds: lesion ≥30 mm, lytic destruction ≥50% of cortex, or persistent pain with weight-bearing after radiotherapy. Prophylactic fixation outperforms post-fracture repair on every functional outcome metric. Refer before the fracture happens.
Before starting any cancer patient on monthly zoledronate or denosumab, obtain dental clearance. ONJ risk is approximately 1% per year for both agents, and most cases involve recent tooth extraction or poor oral hygiene. If extraction cannot be avoided during therapy, suspend the bone-targeted agent until the socket heals.
For breast cancer patients asking about adjuvant bone agents: bisphosphonates reduce breast cancer mortality by more than one in six deaths at 10 years, but only in postmenopausal women or those on ovarian suppression. Denosumab has no adjuvant survival benefit.
These 2020 ESMO Clinical Practice Guidelines synthesize evidence-based recommendations for managing bone health across the cancer spectrum. They cover diagnosis and imaging of bone metastases, indications for bone-targeted agents, surgical decision-making for pathologic fractures, radionuclide therapy, adjuvant bisphosphonate use in early breast cancer, and prevention of cancer treatment-induced bone loss.
Two denosumab rules every orthopedic trainee must know: first, denosumab must stay on a strict every-4-weeks schedule because it does not accumulate in bone — any gap in dosing risks rebound osteolysis. Second, when denosumab is stopped after more than 6 months, bridging with a single dose of zoledronate 4–5 mg is required to prevent rebound vertebral fractures. Neither rule applies to bisphosphonates.
When evaluating a long bone lesion in a cancer patient, apply the prophylactic fixation thresholds: lesion ≥30 mm, lytic destruction ≥50% of cortex, or persistent pain with weight-bearing after radiotherapy. Prophylactic fixation outperforms post-fracture repair on every functional outcome metric. Refer before the fracture happens.
Before starting any cancer patient on monthly zoledronate or denosumab, obtain dental clearance. ONJ risk is approximately 1% per year for both agents, and most cases involve recent tooth extraction or poor oral hygiene. If extraction cannot be avoided during therapy, suspend the bone-targeted agent until the socket heals.
For breast cancer patients asking about adjuvant bone agents: bisphosphonates reduce breast cancer mortality by more than one in six deaths at 10 years, but only in postmenopausal women or those on ovarian suppression. Denosumab has no adjuvant survival benefit.